Severe anemia when blood transfusion is not possible is one of the more unusual FDA-recognized HBOT uses. It is rare. But it can be lifesaving in patients who refuse blood or who cannot get a match.
This page lays out the evidence for HBOT in severe anemia, the bridge-therapy role, and how the case for treatment is built on physiology and case series rather than large trials.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (one of 14) |
| UHMS classification | Tier 2 — approved indication |
| Typical protocol | 2.0-2.5 ATA, 90 min, repeated every 6-12 hours until red cell recovery |
| Medicare coverage | Covered under LCD L33532, 2025 when transfusion not possible |
| Insurance prior auth | Often waived in emergency setting; documentation of refusal or contraindication needed |
| Evidence grade | GRADE C (case series, strong physiology, no RCT possible) |
The evidence
The severe-anemia HBOT data rests on case reports and one formal systematic review. No randomized trial exists because patients in this setting cannot ethically be assigned to no treatment.
The Greensmith Anaesthesia case report, 1999, PMID 10460565 is the classic citation. A 20-year-old Jehovah's Witness arrived with a hemoglobin of 3.5 g/dL and was treated with chamber sessions every 6 hours until red cell recovery.
The Van Meter systematic review in Undersea Hyperb Med, 2005, PMID 15796315 pooled 35 publications and graded each by AHA and NCI-PDQ standards. The review backed HBOT as a bridge therapy in patients who could not receive blood.
A Hart article on resuscitation with HBOT in low hemoglobin, PMID 16369632 framed the modern approach. Treatment is guided by oxygen debt, not a fixed hemoglobin trigger.
The Frontiers in Medicine 2024 review on HBOT in severe anemia updated the case. The authors covered the role in ATLS and ACLS care for severely injured patients who cannot receive blood.
The PMC 2021 case report on HBOT for pernicious anemia added a chronic-anemia case to the literature. The patient was a bloodless medicine patient with hemoglobin below 4 g/dL.
The StatPearls 2024 reference on hyperbaric therapy in blood loss anemia sums up the standard approach. The reference covers dosing, monitoring, and stopping points.
The UHMS chapter on severe anemia lays out the formal indication. The Society backs HBOT as a bridge until the body can make new red cells.
The Greensmith Anesthesiology 2000 organ dysfunction reversal report reported organ recovery during chamber treatment. The case helped set the bridge-therapy template.
A Tibbles and Edelsberg NEJM review, 1996 framed the general HBOT evidence base. The review noted that plasma alone carries enough dissolved oxygen at 3 ATA to feed tissues without red cells.
The UHMS HBO Indications page, current 2026 lists severe anemia as one of the 14 approved uses.
The pattern is consistent. HBOT can sustain a patient with very low hemoglobin until red cells recover. The case for treatment is built on physiology, case series, and the absence of any other choice when blood is not on the table.
Mechanism of action
Red blood cells carry most of the oxygen the body uses. When red cell counts fall below a critical level, tissues starve even with normal lung function.
The plasma — the liquid part of blood — carries only a small fraction of total oxygen at room pressure. At 3 ATA breathing 100% oxygen, plasma carries about 6 mL of oxygen per 100 mL of blood. That is enough to feed tissues on its own.
Chamber treatment turns plasma into a temporary oxygen carrier. Tissues can survive low red cell counts because the plasma takes over the carrier role.
The bridge holds while the body builds new red cells. Iron, B12, folate, and EPO support speed up the rebuild. HBOT buys time for those treatments to work.
The mechanism explains the dosing pattern. Sessions repeat every 6 to 12 hours, not daily, because plasma oxygen drops back to baseline within minutes of leaving the chamber.
Typical protocol
Standard treatment runs 2.0 to 2.5 ATA for 90 minutes per session. Sessions repeat every 6 to 12 hours until red cell counts recover enough to support life without the chamber.
Treatment is paired with maximal red cell support — iron, B12, folate, and erythropoietin (EPO) — to drive new red cell growth. EPO is the main driver in patients with normal kidneys.
Sessions continue until hemoglobin reaches a safer threshold or the patient can take blood again. Most cases run 2 to 7 days of round-the-clock sessions.
The exact session count is set by the patient's response. Some patients need only a few sessions; others need a week of intensive cycling.
Insurance and cost
Medicare covers severe anemia under CMS NCD 20.29, 2017 and the related LCD L33532. Cover is set when blood transfusion is not possible for medical, religious, or supply reasons.
Cost per session runs $1,000 to $3,000 because of the intensive care setup and the every-6-hour cycling. A 5-day course can run $30,000 to $60,000.
Commercial insurance generally follows Medicare for this use. Prior auth is often waived in the emergency setting. Documentation of refusal or contraindication comes after the fact.
Most patients are critically ill when treatment starts. The HBOT bill is folded into the larger hospital care cost and is rarely the patient's first concern.
Where to get it
Severe-anemia HBOT runs at hospital-based hyperbaric centers with 24-hour staffing. The center must be able to hold a critically ill patient through repeated long sessions.
The UHMS-accredited facility directory, current 2026 lists fit centers. The subset with 24-hour emergency intake is smaller.
Most large academic medical centers have a chamber program that can take these patients. Rural hospitals often need to transfer.
For chamber type details, see our FDA-cleared chambers list. Severe-anemia care asks for a multiplace chamber that can hold a critically ill patient with care lines.
See our UHMS accreditation primer for what the credential means in practice.
Limitations and contraindications
Untreated lung collapse is an absolute limit. Critically ill patients often have lung issues that need imaging and care before chamber treatment.
Active seizure disorder is a relative limit. Oxygen toxicity seizures can happen during long high-pressure sessions, mainly in patients with prior brain injury.
Patients with severe lung disease may not tolerate the long oxygen exposure. The team must judge tolerance on a session-by-session basis.
Pregnancy is not a hard limit but asks for careful dosing. Fetal oxygen levels can rise enough to be a concern if sessions run too long.
The harder limit is the underlying cause. HBOT does not fix the source of bleeding or marrow failure. Surgical cleanup of bleeding, EPO for marrow support, and other steps must run alongside chamber care.
Active research
ClinicalTrials.gov studies on HBOT in severe anemia, current 2026 cover plans for trauma resuscitation, post-surgical blood loss, and bloodless medicine programs.
A focus area is the role of HBOT in major trauma cases where blood supply is short or the patient is far from a blood bank. Military and rural-medicine programs lead this work.
Another focus is the role of HBOT in chronic anemia that is too severe for outpatient care but not in active blood loss. Sickle-cell crisis is one such area, though the data there is still thin.
How this compares to off-label HBOT uses
Severe anemia HBOT is a narrow but well-established FDA-recognized use. The physiology is direct (plasma oxygen replaces red cell oxygen), the dosing is clear, and the role is settled as a bridge while red cells recover.
This is very different from off-label HBOT for chronic wellness or anti-aging. Severe anemia HBOT fixes a clear oxygen-carrier failure that responds to a clear physical fix — pressure plus 100% oxygen. Off-label uses do not target such a clear failure.
For context on how off-label HBOT marketing splits from clinical data, read our analysis of institutional silence on HBOT and our arterial gas embolism evidence atlas, another emergency use that runs on the same plasma-oxygen physiology.
The honest summary: HBOT for severe anemia is a niche but real use. The case for treatment is built on physiology and case series, and the role is bridge therapy until red cells recover.
Frequently asked questions
When is HBOT used instead of a blood transfusion?
When transfusion is not possible. The most common cases are Jehovah's Witness patients who refuse blood on religious grounds, patients with rare blood types who cannot get a match, and trauma cases where blood supply is short.
How fast does it work?
Tissue oxygen rises within minutes of starting a session. But the effect drops back to baseline within minutes of leaving the chamber. That is why sessions repeat every 6 to 12 hours until red cells recover.
Will insurance cover this?
Yes. Severe anemia when transfusion is not possible is one of the 14 FDA-recognized uses. Medicare and most commercial plans cover it. Prior auth is often waived in emergency cases.
How many sessions are needed?
Most patients run 5 to 20 sessions over 2 to 7 days. The total depends on how fast red cells recover with EPO and iron support. Sessions stop when hemoglobin reaches a safer level.
Can a soft-shell wellness chamber treat this?
No. Severe-anemia care asks for 2.0 ATA or higher in a medical chamber that can hold a critically ill patient with care lines. Soft-shell chambers reach only 1.3 ATA. That is not enough to drive plasma oxygen high enough to replace red cell carriage.
Sources
- Greensmith Anaesthesia Case Report, 1999
- Van Meter Systematic Review, 2005
- Hart Resuscitation Article, 2005
- Frontiers HBOT Severe Anemia Review, 2024
- PMC Pernicious Anemia Case Report, 2021
- StatPearls Hyperbaric Therapy Blood Loss Anemia, 2024
- UHMS Severe Anemia Chapter, current
- Greensmith Anesthesiology Organ Dysfunction Report, 2000
- Tibbles and Edelsberg NEJM Review, 1996
- UHMS HBO Indications, current 2026
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- CMS LCD L33532, 2025
Medical disclaimer
This page is medical journalism, not medical advice. Severe anemia when blood transfusion is not possible is a life-threatening case that asks for hospital care. HBOT is a bridge therapy and does not replace red cell support. Talk to a hyperbaric medicine doctor and the treating team about care choices.